PT  - JOURNAL ARTICLE
ED  - ,
TI  - Leukotriene receptor antagonists - an update
AID  - 10.1136/dtb.2005.431185
DP  - 2005 Nov 01
TA  - Drug and Therapeutics Bulletin
PG  - 85--88
VI  - 43
IP  - 11
4099  - http://dtb.bmj.com/content/43/11/85.short
4100  - http://dtb.bmj.com/content/43/11/85.full
SO  - Drug Ther Bull2005 Nov 01; 43
AB  - Relevant BNF sections: 3.1, 3.3.2Montelukast (Singulair - MSD) and zafirlukast (Accolate - AstraZeneca) are oral leukotriene receptor antagonists, licensed for the treatment of patients with asthma. In 1998, soon after their launch, we concluded that there was insufficient evidence to clearly define their place in treatment.1 Here, we reconsider their role in adults and children with asthma in the light of more recent evidence.